Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge

Journal of Medical Primatology

Volumn 31, Issue 4-5, 2002, Pages 205-216

  Lifson, J D ^a   Piatak Jr , M ^a   Rossio, J L ^a   Bess Jr , J ^a   Chertova, E ^a   Schneider, D ^a   Kiser, R ^a   Coalter, V ^a   Poore, B ^a   Imming, R ^a   Desrosiers, R C ^b   Henderson, L E ^a   Arthur, L O ^a  

^a SAIC FREDERICK INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Inactivated; SIV; Vaccine

Indexed keywords

ADJUVANT; CD8 ANTIGEN; GLYCOPROTEIN GP 120; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DELETION; IMMUNOGENICITY; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SUPPRESSOR CELL; VIRION; VIRUS INACTIVATION; VIRUS MUTANT; VIRUS STRAIN;

ADMINISTRATION, RECTAL; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, ENV; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MALE; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VACCINES, ATTENUATED; VIRAL LOAD;

ANIMALIA; MACACA; MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0036694204     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0684.2002.02007.x     Document Type: Article

References (31)

1. Characterization of clones of HIV-1 infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein
2. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
3. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine
4. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations
5. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication
6. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response
7. SU) of Human Immunodeficiency Virus type 1 (HIV-1) and Simian Immunodeficiency Virus (SIV) are stably associated with transmembrane envelope glycoproteins (TM) in purified readily shed
8. Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus
9. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine
10. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus
11. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): Differential intracellular fate of virions in mature and immature DCs
12. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention
13. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites
14. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge
15. Inactivated whole SIV vaccine in macaques: Evaluation of protective efficacy against challenge with cell-free virus or infected cells
16. Dendritic cells resurrect antigens from dead cells
17. Activation of HIV-1 specific CD4+ and CD8+ T cells by human dendritic cells: Roles for crosspresentation and non-infectious HIV-1 virus
18. Containment of SIV infection: Cellular immune responses and protection from re-challenge following transient post-inoculation antiretroviral treatment
19. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
20. Ability of the V3 loop of Simian Immunodeficiency Virus to serve as a target for antibody mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4
21. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV specific T cell responses
22. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins
23. The role of nonhuman primates in the development of an AIDS vaccine
24. mac-induced immunodeficiency
25. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells
26. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge
27. A role for carbohydrates in immune evasion in AIDS
28. Inactivation of HIV-1 infectivity with preservation of conformational and functional integrity of virion surface proteins
29. Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine
30. Anti-cell antibody in macaques
31. Plasma SIV RNA viral load by real time quantification of product generation in RT PCR